Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters

L. R. Morgan, P. S. Schein, P. V. Woolley, D. Hoth, J. Macdonald, M. Lippman, L. E. Posey, R. W. Beazley

Research output: Contribution to journalArticlepeer-review

83 Scopus citations


Tamoxifen (NSC 180973; ICI 46474) can provide palliation to patients with advanced breast cancer whose tumors contain estrogen binding proteins (EBP). The drug is most effective in patients with bone metastasis and minimal prior therapy. In the present study, 72 patients with advanced breast cancer were evaluated for their response to oral tamoxifen therapy administered at a dose of 20 mg twice daily. Twenty eight of 72 patients (38%) demonstrated objective responses to tamoxifen therapy. For patients with a positive EBP and no prior chemotherapy, eight of 11 (74%) responded. No patient possessing a tumor negative for EBP achieved a remission. Patients with tumors that possessed normal arylsulfatase B and glucose 6 phosphate dehydrogenase enzyme activities responded most favorably to tamoxifen therapy. These results demonstrate that tamoxifen is effective in the treatment of patients with advanced breast cancer, and EBP and specific enzymes might be useful in selecting the patients for hormone manipulation.

Original languageEnglish (US)
Pages (from-to)1437-1443
Number of pages7
JournalCancer Treatment Reports
Issue number10
StatePublished - Dec 1 1976

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters'. Together they form a unique fingerprint.

Cite this